Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors

Trial Profile

A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs IM 156 (Primary)
  • Indications Glioblastoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoMet Therapeutics
  • Most Recent Events

    • 18 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Aug 2019.
    • 18 Dec 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2019.
    • 05 Jun 2018 Trail design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top